



Contents lists available at ScienceDirect

Life Sciences

journal homepage: www.elsevier.com/locate/lifescie

Evidence for biased agonists and antagonists at the endothelin receptors

Janet J. Maguire

Experimental Medicine and Immunotherapeutics, Level 6 ACCI, Box 110 Addenbrooke's Hospital, Cambridge CB2 0QQ, UK

ARTICLE INFO

Article history:

Received 30 October 2015

Received in revised form 22 January 2016

Accepted 16 February 2016

Available online xxx

Keywords:

G protein coupled receptors

Endothelin

ET_A

ET_B

Biased agonism

Biased antagonism

β-Arrestin

Bosentan

Pathway selectivity

IRL1620

ABSTRACT

Biased ligands represent a new strategy for the development of more effective and better tolerated drugs. To date there has been a paucity of research exploring the potential of ligands that exhibit either G protein or β-arrestin pathway selectivity at the endothelin receptors. Re-analysis of data may allow researchers to determine whether there is existing evidence that the endogenous ET peptides or currently available agonists and antagonists exhibit pathway bias in a particular physiological or disease setting and this is explored in the review. An alternative to molecules that bind at the orthosteric site of the ET receptors are cell penetrating peptides that interact with a segment of an intracellular loop of the receptor to modify signalling behaviour. One such peptide IC2B has been shown to have efficacy in a model of pulmonary arterial hypertension. Finally, understanding the molecular pathways that contribute to disease is critical to determining whether biased ligands will provide clinical benefit. The role of ET_A signalling in ovarian cancer has been delineated in some detail and this has led to the suggestion that the development of ET_A G protein biased agonists or β-arrestin biased antagonists should be explored.

© 2016 Published by Elsevier Inc.

1. Introduction

Our understanding of how ligands interact with G protein coupled receptors is evolving, particularly the recognition that some have the ability to preferentially activate a subset of intracellular signalling cascades – so called pathway biased ligands [1]. Additionally, it is now accepted that recruitment of β-arrestin that occurs following activation of the majority of GPCRs not only results in receptor desensitisation and subsequent internalisation but may also contribute to cellular responses involved in normal physiology and disease such as cell migration and proliferation [2]. Therefore, exploiting ligand bias is likely to lead to the development of more effective and better tolerated medicines. This has so far been most clearly demonstrated for the μ-opioid receptor where the agonist TRV130, a molecule that discriminates between beneficial analgesia and detrimental adverse effects such as respiratory depression and nausea, exhibited an improved therapeutic profile compared to morphine in a randomized, double-blind, placebo-controlled, crossover study in healthy volunteers [3]. Whereas bias has been considered a property of synthetic ligands it has recently been reported that for example endogenous opioids also show bias at the μ-opioid receptor [4] indicating that the presence of multiple ligands for a receptor, rather than simply representing physiological redundancy, may allow for nuanced cell specific signalling. Distinct roles for

the three endogenous endothelin (ET) peptides are emerging in development and in, for example, ovarian physiology but whether pathway bias may contribute to the physiology and pathophysiology of the endogenous peptides in the ET system has not been explored. In contrast the potential for targeting the endothelin receptors with synthetic biased ligands is starting to be considered. This brief review discusses current research on biased signalling at the ET receptors and therapeutic areas of interest.

2. ET receptors and probe dependence

Some of the pharmacology of the endothelin receptors has over the last 20 years been described as atypical; not conforming to the basic tenets of receptor pharmacology. Particularly, this has been in differences in the behaviour of the endogenous peptides and synthetic agonists with respect to reversal by washout or blockade/reversal of responses by antagonists in *in vitro* studies [5,6]. It is now apparent that for a particular receptor multiple active conformations, rather than just one, are possible and ligands can stabilize different conformations of a receptor that may activate subsets of available down-stream pathways. Therefore, some of the atypical pharmacology reported for ET receptors may be consistent with these agonists showing a degree of functional selectivity, although differences in ligand-receptor kinetics may also contribute to these observations. Additionally, because of the allosteric nature of the interaction of ligand-GPCR-intracellular protein (e.g. G protein) affinity measured in binding assays may differ from affinity measured

E-mail address: jjm1003@medschl.cam.ac.uk.




Fig. 1. Concentration response curves to ET-1 (●), ET-2 (■), ET-3 (▲) and S6b (▼) in (A) the human endothelium-denuded saphenous vein and (B) an ET_A-mediated β-arrestin recruitment assay. Data are expressed as a percent of the maximum response of ET-1 in each assay and data points are the mean ± s.e.m. of 3–13 experiments.

in functional assays, specifically if different agonists stabilize particular receptor conformations then this allows the potential for orthosteric antagonists to demonstrate agonist specific functional affinities – consistent with previously reported atypical pharmacology of probe dependence [7].

3. Calculating ligand bias for the endogenous ET peptides and related sarafotoxin 6b at the ET_A receptor

There has been at least one report *in vitro* that ET peptides exhibit bias at the ET_A receptor with ET-1 and ET-2 suggested to elicit their long lasting constrictor responses via different mechanisms that was also vascular bed dependent [8]. We have previously published data on both the potency and efficacy of endothelin peptides and sarafotoxins as constrictors of human saphenous vein [9] and in β-arrestin recruitment assays [10]. These data highlighted differences in the relative potencies and efficacies of these agonists in the ET_A mediated constrictor and β-arrestin recruitment assays indicative of bias. Several methods for determining pathway bias from such data have been reported including determination of transducer coefficients τ/K_A , as described by van Westhuizen and colleagues [11]. We have applied this method to our existing data to determine whether the endogenous ET peptides and related sarafotoxin 6b (S6b) show any evidence of bias in the G protein dependent vasoconstrictor assay and G protein independent β-arrestin recruitment assay. Determining bias requires designation of a reference compound that is preferably the endogenous ligand. For the cardiovascular ET_A receptor the most appropriate reference ligand is ET-1. All data are expressed as a % of the maximum ET-1 response and analysed as described [10], to obtain values of $\log_{10}(\tau/K_A)$ that are used for subsequent determination of bias factors. Fig. 1 shows that whilst ET-1, ET-2 and S6b are full agonists in the constrictor assay (the ET-3 curve is incomplete at the maximum possible bath concentration) ET-3 and S6b are both partial agonists in the β-arrestin assay.

Compared to ET-1, all agonists tested showed a 2–4 fold bias for the G protein constrictor assay compared to the β-arrestin assay (Table 1). This preliminary analysis indicated that at least modest pathway bias for endogenous ET peptides is possible, however the physiological

significance of this, if any, requires more comprehensive analysis of data for ET-1, ET-2 and ET-3 in a broader range of relevant pathway specific assays.

4. Ligand bias at the ET_B receptor

There are currently no published data exploring biased agonism at the ET_B receptor. There are a number of ET_B agonists available for study including the endogenous peptide ET-3 and related sarafotoxin 6c (S6c) in addition to peptide agonists such as BQ3020 and IRL 1620. IRL-1620 is of particular significance as it is under investigation in a number of therapeutic areas with efficacy demonstrated in animal models of stroke [12] and as an adjunct for improved delivery of chemotherapy targeting solid tumours [13]. It would therefore be of interest to determine the relative effect of these agonists in a number of disease relevant pathways, with comparison to ET-3 responses to determine evidence of bias. These types of studies may highlight any differences between the agonists investigated that could be used either to further understand the signalling of importance to disease progression or to refine clinical efficacy of drugs by reducing on target detrimental effects through defined pathway activation.

5. Do ET receptor antagonists show pathway bias?

Of perhaps more consequence for the ET system is the possibility that antagonists exhibit pathway bias. This has been reported for the dual ET_A/ET_B antagonist bosentan. In human cloned receptors bosentan exhibits a modest 20 fold selectivity for the ET_A receptor [14] and in human heart that expresses both receptor subtypes bosentan competes for the binding of [¹²⁵I]ET-1 with a single affinity (K_D : 78 nM) indicating that it does not distinguish between the native receptors in this tissue [15]. In human blood vessels that express predominantly ET_A receptors bosentan exhibited, as expected, 2–20 fold higher affinity than in heart with K_D of 32 nM in saphenous vein [16] and 3 nM in coronary artery [17]. In contrast bosentan was a much less effective antagonist than would be predicted from its binding affinity in both ET_A mediated vasoconstriction in human saphenous vein and coronary artery [15], in ET_B mediated smooth muscle contraction [14] and ET_B β-arrestin recruitment experiments [10] with a functional affinity of about 2 μM in all these assays. Unexpectedly, in the ET_A mediated β-arrestin assay bosentan was 200 fold more effective an antagonist with K_B of 10 nM [10] suggesting that bosentan is an ET_A β-arrestin biased antagonist. It is interesting to speculate that the relative effectiveness of bosentan in treatment of pulmonary arterial hypertension compared to its generally low potency as an antagonist *in vitro* may in part be explained by the greater antagonism of detrimental ET_A linked β-arrestin mediated ERK1/2 signalling [18] that could contribute to smooth muscle cell proliferation in this disease.

6. Alternative strategies: cell penetrating peptides as biased antagonists

Cell penetrating peptides (CPPs) are a superfamily of peptides that interact with an intracellular segment of a G protein coupled receptor

Table 1
Bias analysis for the relative effectiveness of endothelin peptides in the human saphenous vein constrictor and ET_A-mediated β-arrestin recruitment assays.

	Saphenous vein constrictor assay			β-Arrestin recruitment assay			Saphenous vein vs β-arrestin	
	LogR	ΔLogR	RE	LogR	ΔLogR	RE	ΔΔLogR	Bias factor
ET-1	8.55 ± 0.15	0 ± 0.22	1	9.46 ± 0.08	0 ± 0.11	1	0 ± 0.24	1
ET-2	8.26 ± 0.21	−0.29 ± 0.26	0.51	8.67 ± 0.03	−0.79 ± 0.08	0.16	0.49 ± 0.27	3.1
ET-3	6.80 ± 0.37	−1.75 ± 0.40	0.018	7.11 ± 0.03	−2.35 ± 0.08	0.0045	0.60 ± 0.41	4.0
S6b	8.11 ± 0.12	−0.44 ± 0.12	0.36	8.68 ± 0.06	−0.78 ± 0.10	0.17	0.34 ± 0.15	2.2

R = (τ/K_A), the transducer coefficient, where τ is an index of agonist efficacy and K_A is functional affinity of the agonist. ΔLogR is the relative LogR values of test agonists compared to the reference agonist in a particular assay. ΔΔLogR is the relative ΔLogR values for particular agonists between assays. The bias factor is determined as $10^{\Delta\Delta\text{LogR}}$. Analysis performed as described by van der Westhuizen and colleagues [11].

Download English Version:

<https://daneshyari.com/en/article/5841295>

Download Persian Version:

<https://daneshyari.com/article/5841295>

[Daneshyari.com](https://daneshyari.com)